Open Monoclonal Technology, Inc. (OMT) today announced an antibody
discovery collaboration with Merck KGaA. OMT and Merck KGaA have entered
into a collaboration whereby OMT will use its OmniRats™ to generate
antibodies against several targets selected by Merck KGaA. Merck KGaA
has the rights to further develop and commercialize the antibodies
derived from the OmniRat™ as therapeutic and diagnostic products. Under
the terms of the agreement, OMT will receive upfront payment,
success-based milestones, and royalties.
"We are pleased to be collaborating with Merck KGaA. OMT's OmniRat™
generates antibodies with great specificity, affinity and
manufacturability. Our partners are looking for technologies that can
eliminate time-consuming humanization of antibodies or optimization of
leads identified using display technology. The OmniRat™ can save
significant development time and is available for all targets", said
Roland Buelow, Founder and CEO of OMT.
Open Monoclonal Technology, Inc.